CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor–modified T (CAR-T)-Cell Immunotherapy-Reference-Cited by-同舟云学术

CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor–modified T (CAR-T)-Cell Immunotherapy

Published:2021-08-09 Issue:9 Volume:44 Page:351-354
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Heldman Madeleine R.,Ma Jimmy,Gauthier Jordan,O’Hara Riley A.,Cowan Andrew J.,Yoke Leah M.,So Lisa,Gulleen Elizabeth,Duke Elizabeth R.,Liu Catherine,Turtle Cameron J.,Hill Joshua A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference10 articles.

1. How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies;Hill;Blood,2020

2. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy;Hill;Blood,2018

3. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells;Park;Clin Infect Dis,2018

4. Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation;Martins;Science,2019

5. Reactivation of multiple viruses in patients with sepsis;Walton;PLoS One,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy;Blood Advances;2024-07-12

2. Overview of infectious complications among CAR T- cell therapy recipients;Frontiers in Oncology;2024-07-03

3. Antimicrobial Stewardship in Immunocompromised Patients;Infectious Disease Clinics of North America;2023-12

4. Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy;Clinical Infectious Diseases;2023-11-17

5. Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies;Transplant Infectious Disease;2023-10-03